Immatics N.V.
Clinical-stage biopharma developing T cell receptor immunotherapies for cancer.
IMTX | US
Overview
Corporate Details
- ISIN(s):
- NL0015285941
- LEI:
- Country:
- United States of America
- Address:
- PAUL EHRLICH-STRASSE 15, 72076 TUBINGEN
- Website:
- https://immatics.com/
- Sector:
- Manufacturing
Description
Immatics N.V. is a clinical-stage biopharmaceutical company that develops targeted immunotherapies for cancer. The company's approach combines the discovery of novel cancer targets with the development of corresponding T cell receptors (TCRs) to treat solid tumors. It operates through two primary therapeutic modalities: Adoptive Cell Therapies (ACT), which involve engineering a patient's T cells, and TCR Bispecifics, which are off-the-shelf biologics. Immatics is a leader in the precision targeting of PRAME, a protein expressed in over 50 different types of cancer. Its clinical pipeline includes multiple product candidates targeting PRAME, aiming to address significant unmet medical needs for a broad patient population.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Immatics N.V. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Immatics N.V.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Immatics N.V. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
